natgillin/translations-raw huggingface dataset:
• Make sure the plunger is pushed all the way down, until the stopper reaches the bottom of the syringe and all of the solution is injected.
• Poskrbite, da je bat potisnjen do konca dol, dokler zamašek ne doseže dna brizge in je vsa raztopina injicirana.
Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of mepolizumab.
Encimi citokroma P450, iztočne črpalke in mehanizmi vezave na proteine ne sodelujejo pri očistku mepolizumaba.
The trade name (Nucala) and batch number of the administered product should be clearly recorded in the patient file.
Zaščiteno ime (Nucala) in serijska številka uporabljenega zdravila morata biti jasno zabeležena v bolnikovi dokumentaciji.
Inspection window (medicine inside)
Okence za ogled (zdravilo znotraj)
Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques.
Zdravilo Nucala si lahko injicira bolnik sam, ali mu ga injicira negovalec, če zdravnik presodi, da je to primerno, ter če bolnik oziroma negovalec opravita usposabljanje o tehniki injiciranja.
Do not inject within 5 cm of your navel (belly button).
Ne injicirajte v predel 5 cm okrog popka.
These may affect more than 1 in 10 people: • headache
Pojavijo se lahko pri več kot 1 od 10 oseb: • glavobol.
Following repeat subcutaneous administration every 4 weeks, there is approximately a two-fold accumulation at steady state.
Po ponavljajoči se subkutani uporabi na 4 tedne je kopičenje v stanju dinamičnega ravnovesja približno dvakratno.
• Clean your injection site by wiping the skin with an alcohol wipe and allowing the skin to air dry.
• Očistite mesto injiciranja tako, da ga obrišete z alkoholnim robčkom in pustite, da se na zraku posuši.
For storage conditions after reconstitution of the medicinal product, see section 6.3.
Za pogoje shranjevanja zdravila po rekonstituciji glejte poglavje 6.3.
Make sure the white plunger is fully down
Poskrbite, da je bel bat potisnjen do konca dol
If a mechanical reconstitution device (swirler) is used to reconstitute Nucala, reconstitution can be accomplished by swirling at 450 rpm for no longer than 10 minutes.
Če za rekonstitucijo zdravila Nucala uporabljate mehanično napravo, je rekonstitucijo mogoče opraviti z vrtenjem s 450 obrati na minuto, a ne več kot 10 minut.
This medicine is not intended for use in children below 6 years of age.
To zdravilo ni namenjeno za uporabo pri otrocih, mlajših od 6 let.
• Do not remove the needle cap until just before your injection.
• Pokrovček igle odstranite šele tik pred injiciranjem.
Talk to your doctor before using this medicine.
Pred uporabo tega zdravila se posvetujte z zdravnikom.
If you already have a parasitic infection; it should be treated before you start treatment with Nucala.
Če že imate kakšno okužbo s paraziti, jo je treba zdraviti, preden začnete zdravljenje z zdravilom Nucala.
However, in the population pharmacokinetic analysis, there were no indications of an effect of age on the pharmacokinetics of mepolizumab over the age range of 12 to 82 years.
Toda populacijska farmakokinetična analiza ni pokazala, da bi starost vplivala na farmakokinetiko mepolizumaba v starostnem razponu od 12 do 82 let.
By blocking the action of this protein, it limits the production of more eosinophils from the bone marrow and lowers the number of eosinophils in the bloodstream and the lungs.
Zavrtje delovanja te beljakovine zmanjša nastajanje eozinofilcev v kostnem mozgu in njihovo število v krvnem obtoku in pljučih.
After use, the automatic needle guard is activated and pulls up (retracts) the needle.
Po uporabi se avtomatski ščitnik igle aktivira in potegne
Common Rare
pogosti redki
Patients were required to have a history of two or more severe asthma exacerbations requiring oral or systemic corticosteroid treatment in the past 12 months and reduced lung function at baseline (pre-bronchodilator FEV1<80% in adults and <90% in adolescents).
Bolniki so morali imeti anamnezo vsaj dveh hudih poslabšanj astme, ki so zahtevala peroralno ali sistemsko zdravljenje s kortikosteroidi, v preteklih 12 mesecih in izhodiščno zmanjšano delovanje pljuč (FEV1 pred bronhodilatatorjem < 80 % pri odraslih in < 90 % pri mladostnikih).
The primary endpoint was the frequency of clinically significant exacerbations of asthma and the reductions for both mepolizumab treatment arms compared to placebo were statistically significant (p<0.001).
Primarni opazovani dogodek je bila pogostnost klinično pomembnih poslabšanj astme; zmanjšanje v obeh skupinah z mepolizumabom je bilo v primerjavi s placebom statistično značilno (p < 0,001).
You or your caregiver should inject the next dose of Nucala as soon as you remember.
Vi (ali vaš negovalec) morate naslednji odmerek zdravila Nucala injicirati, čim se spomnite.
Exacerbation reduction MEA115588 (MENSA) study
Študija zmanjšanja poslabšanj MEA115588 (MENSA)
Consistent with the potentially immunogenic properties of protein and peptide therapeutics, patients may develop antibodies to mepolizumab following treatment.
Glede na možno imunogenost beljakovinskih in peptidnih zdravil se lahko bolnikom po zdravljenju pojavijo protitelesa proti mepolizumabu.
The two exacerbations studies MEA112997 and MEA115588 enrolled a total of 1192 patients, 60% females, with a mean age of 49 years (range 12- 82).
Dve študiji poslabšanj (MEA112997 in MEA115588) sta skupaj zajeli 1192 bolnikov, 60 % žensk, s povprečno starostjo 49 let (razpon: od 12 do 82).
For children aged 6-11 years, contact your doctor who will prescribe the recommended dose of Nucala which will be administered by a nurse or doctor.
Za otroke v starosti od 6 do 11 let se obrnite na zdravnika; predpisal bo priporočen odmerek zdravila Nucala,
• Hold the pen with its inspection window facing towards you, so you can see it, and with the yellow needle guard facing down.
• Držite peresnik tako, da je okence za ogled obrnjeno k vam in ga lahko vidite, in da rumeni ščitnik igle gleda dol.
Table 4: Results of the primary and secondary endpoints in MEA115575
Preglednica 4: Rezultati primarnih in sekundarnih opazovanih dogodkov v študiji MEA115575
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded in the patient file.
Za izboljšanje sledljivosti bioloških zdravil je treba ime in številko serije uporabljenega zdravila jasno zabeležiti v bolnikovi dokumentaciji.
There are limited pharmacokinetic data available in the paediatric population (59 subjects with eosinophilic esophagitis, 55 subjects with severe refractory eosinophilic asthma).
Farmakokinetičnih podatkov za pediatrično populacijo je malo (59 preiskovancev z eozinofilnim ezofagitisom, 55 preiskovancev s težko trdovratno eozinofilno astmo).
Hypersensitivity reactions (systemic allergic)*
Bolezni imunskega sistema preobčutljivostne reakcije (sistemske alergijske)* anafilaksija**
There are limited data available in patients with creatinine clearance values <50 mL/min.
Podatkov o bolnikih z očistkom kreatinina < 50 ml/min je malo.
No decrease in OCS/lack of asthma control/ withdrawal from treatment Odds ratio (95% CI) p-value
Brez zmanjšanja PKS/odsotnost urejenosti astme/umik iz zdravljenja Razmerje obetov (95 % IZ) Vrednost p
Mepolizumab 100 mg (subcutaneous) N= 194
mepolizumab 100 mg (subkutano) N = 194
Patients continued to receive their existing asthma medicine during the studies.
V obeh študijah so bolniki nadaljevali z uporabo svojega dotedanjega zdravila za astmo.
Paediatric pharmacokinetics was largely predictable from adults, after taking into account bodyweight.
Pediatrična farmakokinetika je bila v veliki meri predvidljiva na podlagi farmakokinetike pri odraslih, upoštevaje telesno maso.
Reconstitution is typically complete within 5 minutes after the sterile water has been added, but it may take additional time.
Rekonstitucija je praviloma dokončana v 5 minutah po dodatku sterilne vode,
Eosinophils are thought to be associated with immune system responses to some parasitic infections.
Eozinofilci so domnevno povezani z odzivom imunskega sistema na nekatere okužbe s paraziti.
This will allow the plunger to come up and the needle to retract (rise up) into the body of the syringe.
To bo omogočilo, da se bat dvigne in da se igla umakne (dvigne)
• chest tightness, cough, difficulty breathing
• tiščanje v prsnem košu, kašelj, težko dihanje,
The potential for interactions with mepolizumab is therefore considered low.
Možnost za medsebojno delovanje zdravil z mepolizumabom je zato majhna.
In the population pharmacokinetic analysis estimated mepolizumab systemic clearance was 3.1 mL/day/kg.
Sistemski očistek mepolizumaba, ocenjen v populacijski farmakokinetični analizi, je bil 3,1 ml/dan/kg.
• Place the pen straight onto your injection site with the yellow needle guard flat against the surface of your skin, as shown.
• Položite peresnik naravnost na mesto injiciranja, z rumenim ščitnikom igle plosko na površini kože, kot je prikazano.
Data in cynomolgus monkeys demonstrate that mepolizumab crossed the placenta.
Podatki pri opicah cynomolgus kažejo, da mepolizumab prehaja skozi placento.
≥500 cells/µL
≥500 celic/µl n
Other medicines and Nucala
Druga zdravila in zdravilo Nucala
Note: The reconstituted solution must not be shaken during the procedure as this may lead to product foaming or precipitation.
Opomba: Rekonstituirane raztopine med postopkom ne smete pretresati, ker to lahko povzroči penjenje ali precipitacijo zdravila.
Store in a refrigerator (2°C - 8°C).
Shranjujte v hladilniku (2-8 °C).
The proportion of patients on maintenance OCS was 31% and 24%, respectively.
V prvi študiji je vzdrževalne PKS uporabljalo 31 % bolnikov in v drugi 24 %.
This medicine contains less than 1 mmol sodium (23 mg) per 100 mg dose, i.e., it is essentially “sodiumfree”.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 100-mg odmerek, kar v bistvu pomeni "brez natrija".
In a combined analysis of these studies, a 40% reduction in clinically significant exacerbations was observed in adolescents following mepolizumab treatment compared to placebo (rate ratio 0.60; 95% CI: 0.17, 2.10).
V kombinirani analizi teh študij so pri mladostnikih po uporabi mepolizumaba opažali 40 % manj klinično pomembnih poslabšanj kot s placebom (razmerje deležev 0,60, 95 % IZ: 0,17, 2,10).
1st “Click”
“klik”
Do not lift the pen from your skin at this stage, as that may mean you don't get your full dose of medicine.
V tej fazi peresnika ne dvigajte s kože, saj se sicer lahko zgodi, da ne boste dobili celotnega odmerka zdravila.
MEA115575 evaluated the effect of mepolizumab 100 mg administered subcutaneously on reducing the requirement for maintenance oral corticosteroids (OCS) while maintaining asthma control in subjects with severe refractory eosinophilic asthma.
Študija MEA115575 je ocenila učinek 100 mg mepolizumaba, uporabljenega subkutano, na zmanjšanje potrebe po vzdrževalnih peroralnih kortikosteroidih (PKS) med vzdrževanjem urejenosti astme pri bolnikih s težko trdovratno eozinofilno astmo.
Worsening asthma
Poslabšanje astme
Based on population pharmacokinetic analyses, no dose adjustment is required in patients with creatinine clearance values between 50-80 mL/min.
Na podlagi populacijske farmakokinetične analize bolnikom z očistkom kreatinina med 50 in 80 ml/min odmerka ni treba prilagoditi.
Intravenous and subcutaneous administration to monkeys was associated with reductions in peripheral and lung eosinophil counts, with no toxicological findings.
Intravenska in subkutana uporaba pri opicah sta bili povezani z zmanjšanjem perifernega števila eozinofilcev in števila eozinofilcev v pljučih, brez toksikoloških ugotovitev.
Animal studies showed no adverse effects of anti-IL5 treatment on fertility (see section 5.3).
Študije na živalih niso pokazale neželenih učinkov zdravil proti IL5 na plodnost (glejte poglavje 5.3).
This condition is called eosinophilic asthma - the type of asthma Nucala can treat.
To bolezen imenujemo eozinofilna astma - to je vrsta astme, ki jo lahko zdravi zdravilo Nucala.
Lyophilised white powder.
Liofiliziran bel prašek.
Secondary endpoints (weeks 20-24)
Sekundarni opazovani dogodki (20.
The reduction rate with mepolizumab was greater in patients with higher blood eosinophil counts.
Delež zmanjšanj je bil z mepolizumabom večji pri bolnikih z večjim številom eozinofilcev v krvi.
• fainting, dizziness, feeling lightheaded (due to a drop in blood pressure)
• omedlevica, omotica, vrtoglavica (zaradi znižanja krvnega tlaka),
Studies conducted in mice treated with anti-IL-5 antibodies or genetically deficient in IL-5 or eosinophils have not shown impaired ability to clear parasitic infections.
Študije pri miših, ki so dobivale protitelesa proti IL-5, ali jim je genetsko primanjkovalo IL-5 ali eozinofilcev, niso odkrile slabše sposobnosti za odpravo okužb s paraziti.
In patients with asthma the absolute bioavailability of mepolizumab administered subcutaneously in the arm ranged from 74-80%.
Pri bolnikih z astmo je bila absolutna biološka uporabnost mepolizumaba, injiciranega subkutano v roko, od 74 do 80 %.
Mepolizumab is a humanized IgG1 monoclonal antibody degraded by proteolytic enzymes which are widely distributed in the body and not restricted to hepatic tissue.
Mepolizumab je humanizirano monoklonsko protitelo IgG1, ki ga razgradijo proteolitični encimi, ki so v telesu široko porazdeljeni in niso omejeni na jetrno tkivo.
Following administration of a single 100 mg subcutaneous dose in healthy subjects, mepolizumab systemic exposure was comparable between formulations.
Po subkutani uporabi enkratnega 100-mg odmerka pri zdravih preiskovancih je bila sistemska izpostavljenost mepolizumabu med oblikami primerljiva.
Nucala should be prescribed by physicians experienced in the diagnosis and treatment of severe refractory eosinophilic asthma.
Zdravilo Nucala mora predpisati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem težke trdovratne eozinofilne astme.
Nucala is given to you by a doctor, nurse or healthcare professional, as an injection just under the skin (subcutaneously).
Zdravilo Nucala vam bo dal zdravnik, medicinska sestra ali zdravstveni delavec v obliki injekcije tik pod kožo (subkutano).
Animal studies do not indicate reproductive toxicity (see section 5.3).
Študije na živalih ne kažejo reproduktivnih toksičnih učinkov (glejte poglavje 5.3).
Alternatively, swirling at 1000 rpm for no longer than 5 minutes is acceptable.
Druga možnost je vrtenje s 1000 obrati na minuto, a ne več kot 5 minut.
If particulate matter remains in the solution or if the solution appears cloudy or milky, the solution must not be used.
Če v raztopini ostanejo delci, ali če je raztopina motna ali mlečna, je ne smete uporabiti.
Eosinophils may be involved in the immunological response to some helminth infections.
Okužbe s paraziti Eozinofilci so lahko vpleteni v imunski odziv na nekatere okužbe s helminti.
Primary endpoint Frequency of clinically significant exacerbations
Primarni opazovani dogodek Pogostnost klinično pomembnih poslabšanj
Following subcutaneous administration to healthy subjects or patients with asthma, mepolizumab was absorbed slowly with a median time to reach maximum plasma concentration (Tmax) ranging from 4 to 8 days.
Po subkutani uporabi pri zdravih preiskovancih ali bolnikih z astmo se je mepolizumab absorbiral počasi; mediani čas do največje koncentracije v plazmi (tmax) je bil od 4 do 8 dni.
The pre-filled pen or pre-filled syringe must be administered within 8 hours once the pack is opened.
Napolnjeni injekcijski peresnik ali napolnjeno injekcijsko brizgo je treba uporabiti v 8 urah po odprtju pakiranja.
• Slowly push down on the plunger to inject your full dose.
• Počasi potisnite bat dol, da boste injicirali celoten odmerek.
Your doctor or nurse will decide if you or your caregiver can inject Nucala.
Zdravnik ali medicinska sestra bosta presodila, ali lahko zdravilo Nucala injicirate vi ali vaš negovalec.
The posology of Nucala in children and adolescents aged between 6 to 17 years old with severe refractory eosinophilic asthma has been determined by limited efficacy, pharmacokinetic and pharmacodynamic studies and supported by modelling and simulation data (see sections 5.1 and 5.2).
Odmerjanje zdravila Nucala pri otrocih in mladostnikih, starih od 6 do 17 let, s težko trdovratno eozinofilno astmo so določili z omejenimi študijami učinkovitosti, farmakokinetike in farmakodinamike ter potrdili z modeliranjem in simulacijskimi podatki (glejte poglavji 5.1 in 5.2).
• You can inject Nucala into your thighs or abdomen.
• Zdravilo Nucala si lahko injicirate v stegno ali trebuh.
Do not remove the needle cap during this step.
Ne odstranite pokrovčka igle med tem korakom.
Allergic and injection site reactions
Alergijske reakcije in reakcije na mestu injiciranja
Following a single intravenous administration to patients with asthma, the mean systemic clearance (CL) ranged from 1.9 to 3.3 mL/day/kg, with a mean terminal half-life of approximately 20 days.
Po enkratni intravenski uporabi pri bolnikih z astmo je bil povprečni sistemski očistek od 1,9 do 3,3 ml/dan/kg, povprečni terminalni razpolovni čas pa približno 20 dni.
Table 2: Results of primary and secondary endpoints at week 32 in the intent to treat population (MEA115588)
Preglednica 2: Rezultati primarnih in sekundarnih opazovanih dogodkov 32. teden v populaciji znamenom-zdravljenja (MEA115588)
Patients received mepolizumab 100 mg administered subcutaneously, mepolizumab 75 mg administered intravenously or placebo treatment once every 4 weeks over 32 weeks.
Bolniki so prejemali 100 mg mepolizumaba subkutano, 75 mg mepolizumaba intravensko ali placebo enkrat na 4 tedne v obdobju 32 tednov.
Of these 34 subjects: 12 received placebo, 9 received mepolizumab 75 mg intravenously, and 13 received 100 mg subcutaneously.
Od teh 34 preiskovancev jih je 12 dobivalo placebo, 9 jih je dobivalo 75 mg mepolizumaba intravensko in 13 preiskovancev 100 mg subkutano.
Some people with severe asthma have too many eosinophils (a type of white blood cell) in the blood and lungs.
Nekateri bolniki s težko astmo imajo v krvi in pljučih preveč eozinofilcev (eozinofilci so vrsta belih krvnih celic).
Dispose of the used syringe
Zavrzite uporabljeno brizgo
Nucala has no or negligible influence on the ability to drive and use machines.
Zdravilo Nucala nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity.
Mepolizumab je humanizirano monoklonsko protitelo (IgG1, kapa), ki je z veliko afiniteto in specifičnostjo usmerjeno na človeški interlevkin-5 (IL-5).
Do not touch your injection site again until you have finished your injection.
Ne dotikajte se več mesta injiciranja, dokler injiciranja ne dokončate.
Additional maintenance treatments included long-acting beta2 -adrenergic agonists (LABA), leukotriene modifiers, long-acting muscarinic antagonists (LAMA), theophylline, and oral corticosteroids (OCS).
Med dodatnimi vzdrževalnimi zdravili so bili dolgodelujoči agonisti adrenergičnih receptorjev beta2 (LABA), levkotrienski modifikatorji, dolgodelujoči antagonisti muskarinskih receptorjev (LAMA) in peroralni kortikosteroidi (PKS).
The table below presents the adverse reactions from the two placebo-controlled studies in patients receiving mepolizumab 100 mg subcutaneously (n=263).
Spodnja preglednica prikazuje neželene učinke v dveh s placebom kontroliranih študijah pri bolnikih, ki so prejemali 100 mg mepolizumaba subkutano (n=263).
Mepolizumab, the active substance in Nucala, blocks a protein called interleukin-5.
Mepolizumab, učinkovina v zdravilu Nucala, zavre beljakovino, imenovano interlevkin-5.
Oral corticosteroid reduction study MEA115575 (SIRIUS)
Študija zmanjšanja peroralnih kortikosteroidov MEA115575 (SIRIUS)
Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.
Bolnikom je treba naročiti, naj se posvetujejo z zdravnikom, če astma po uvedbi zdravljenja ostaja neurejena ali se poslabša.
1 ml solution in a Type 1 glass syringe with a fixed needle (stainless steel) and passive safety needle guard.
1 ml raztopine v brizgi iz stekla tipa 1 s fiksno iglo (iz nerjavečega jekla) in pasivnim varnostnim ščitnikom igle.
If the solution is cloudy, discoloured or contains particles, the solution should not be used.
Če je raztopina motna, spremenjene barve ali vsebuje delce, se je ne sme uporabiti.
Investigation of a 40 mg subcutaneous dosing regimen administered every 4 weeks in children 6 to 11 years old over a 15-70 kg broad weight range by PK modelling and simulation predicts that the exposure of this dosing regimen would remain on average within 38% of adults at 100 mg.
Raziskava odmerne sheme 40 mg subkutano na 4 tedne pri otrocih, starih od 6 do 11 let in z razponom telesne mase od 15 do 70 kg, s farmakokinetičnim modeliranjem in simulacijo kaže, da bi bila izpostavljenost ob uporabi te odmerne sheme v povprečju 38 % tiste, ki je ugotovljena pri odraslih med uporabo 100 mg.
The stream of sterile water should be directed vertically, onto the centre of the lyophilised cake.
Tok sterilne vode usmerite navpično, na sredino liofiliziranega praška.
Do not expel any air bubbles from the syringe.
Ne iztiskajte zračnih mehurčkov iz injekcijske brizge.
Do not warm the syringe in a microwave, hot water, or direct sunlight.
Peresnika ne segrevajte v mikrovalovni pečici, vroči vodi ali na neposredni sončni svetlobi.
It is used to treat severe asthma in adults, adolescents and children aged 6 years and older.
Uporablja se za zdravljenje težke astme pri odraslih, mladostnikih in otrocih, starih 6 let ali več.
Reduction in the daily OCS dose to ≤5mg/day
Zmanjšanje dnevnega odmerka PKS na ≤ 5 mg/dan
What Nucala is and what it is used for
Kaj je zdravilo Nucala in za kaj ga uporabljamo
Security seals
Varnostni pečat
Since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in hepatic function are unlikely to have any effect on the elimination of mepolizumab.
Mepolizumab se razgradi s široko porazdeljenimi proteolitičnimi encimi, ki niso omejeni na jetrno tkivo, zato ni verjetno, da bi spremembe delovanja jeter vplivale na odstranjevanje mepolizumaba.
Do not use the syringe if left out of the carton for more than 8 hours.
Peresnika ne uporabite, če je bil več kot 8 ur izven škatle.
mg (for a weight < 40kg) or 100 mg (for a weight ≥ 40 kg) was 1.32 and 1.97 times of that observed in adults at 100 mg.
Po subkutanem odmerku 40 mg (za telesno maso < 40 kg) ali 100 mg (za telesno maso ≥ 40 kg) je bila izpostavljenost 1,32-krat oz. 1,97-krat tolikšna kot s 100 mg pri odraslih.
What Nucala looks like and contents of the pack
Izgled zdravila Nucala in vsebina pakiranja
Do not remove the needle cap at this stage.
V tej fazi ne odstranite pokrovčka igle.
Nucala may weaken your resistance to infections caused by parasites.
Zdravilo Nucala lahko poslabša odpornost proti okužbam, ki jih povzročajo paraziti (zajedalci).
In MEA115588 and in the double-blind placebo-controlled study 200862, there were 34 adolescents (12 to 17 years old).
MEA115588 in dvojno slepa, s placebom kontrolirana študija 200862 sta zajeli 34 mladostnikov (starih od 12 do 17 let).
IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils.
IL-5 je glavni citokin, odgovoren za rast in diferenciacijo,
150 to <300 cells/µL
150 do < 300 celic/µl n
If a dose of Nucala is missed Contact your doctor or hospital as soon as possible to re-schedule your appointment.
Če ste izpustili odmerek zdravila Nucala Čim prej pokličite zdravnika ali bolnišnico, da boste dobili nov datum obiska.
What you need to know before you use Nucala 3.
Kaj morate vedeti, preden boste uporabili zdravilo Nucala 3.
Choose your injection site
Izberite mesto injiciranja
Just prior to administration, remove 1 mL of reconstituted Nucala.
Tik pred uporabo izvlecite 1 ml rekonstituiranega zdravila Nucala.